Compare Ginkgo Bioworks Holdings Inc (DNA) vs Tesla, Inc. (TSLA) Price & Performance

DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.

The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.

Tesla (TSLA) trades at $394.76, down 3.18% today amid a bearish technical signal. The stock faces pressure from elevated valuations with a P/E of 362.17 and P/S of 14.25, while recent earnings show mixed results with a Q1 2026 beat but a Q3 2025 miss. Cash flow remains positive at $579M in 2025, though net income margins have compressed to 3.95% from prior years. News highlights focus on autonomous driving approvals in Europe and a potential cheaper EV model.

The outlook is cautious; while analyst consensus is a Buy with a $409.26 target, risks include intense EV competition, execution on AI/robotics bets, and high valuation multiples. Near-term performance hinges on Q2 2026 earnings and delivery growth, with support at $391 and resistance at $399.